All Posts
Low risk of COVID-19 among patients exposed to infected healthcare workers
1 Sep, 2020 | 06:14h | UTC
Commentary on Twitter
Low risk of COVID-19 among patients exposed to infected healthcare workers | #CID The risk of acquiring #SARSCoV2 from an infected HCW was low in a study that tested patients exposed to 60 HCWs with unrecognized SARS-CoV-2 infection. https://t.co/4hppyoXSLC
— Carlos del Rio (@CarlosdelRio7) September 1, 2020
What Is the predictive value of a single nasopharyngeal SARS-CoV-2 PCR swab test in a patient with COVID-like symptoms and / or significant COVID-19 exposure?
1 Sep, 2020 | 06:12h | UTC
Commentary on Twitter
What Is the Predictive Value of a Single Nasopharyngeal SARS-CoV-2 PCR Swab Test in a Patient with COVID-like Symptoms and / or Significant #COVID19 Exposure?
The PCR-test was found to be 87% sensitive, 97% specific, a PPV of 0.98, and a NPV of 0.80 #ofid https://t.co/MGQdzDsd8k— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) August 31, 2020
Viewpoint – Regulatory decision-making on COVID-19 vaccines during a public health emergency
1 Sep, 2020 | 06:08h | UTCRegulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency – JAMA
Viewpoint – Emergency use authorizations during the COVID-19 pandemic: Lessons from hydroxychloroquine for vaccine authorization and approval
1 Sep, 2020 | 06:09h | UTC
A current review of COVID-19 for the cardiovascular specialist
1 Sep, 2020 | 06:06h | UTCA current review of COVID-19 for the cardiovascular specialist – American Heart Journal
#ESCCongress – [Abstract Only] Randomized trial: Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome
1 Sep, 2020 | 06:03h | UTC
Commentary on Twitter
Late breaking at #ESCCongress—Prasugrel-based de-escalation of dual antiplatelet therapy after PCI in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial https://t.co/yvcdB4rZ9x pic.twitter.com/GhPfztHwMX
— The Lancet (@TheLancet) August 31, 2020
Perspective: How to be an ethical scientist
1 Sep, 2020 | 05:55h | UTCHow to be an ethical scientist – Science
Factors associated with risk of recurrent transient global amnesia
1 Sep, 2020 | 05:53h | UTCFactors Associated With Risk of Recurrent Transient Global Amnesia – JAMA Neurology (free for a limited period)
#ESCCongress – [Abstract Only] Randomized trial: Colchicine in patients with chronic coronary disease
1 Sep, 2020 | 06:04h | UTCColchicine in Patients with Chronic Coronary Disease – New England Journal of Medicine
Commentaries: LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease – TCTMD AND Low Dose Colchicine for Secondary Prevention of Cardiovascular Disease 2 – LoDoCo2 – American College of Cardiology
Commentary on Twitter
Patients with chronic coronary disease were randomized to daily colchicine or placebo. Incidence of the composite endpoint of cardiovascular death, spontaneous MI, ischemic stroke, or ischemia-driven coronary revascularization was significantly lower with colchicine. #ESCCongress
— NEJM (@NEJM) August 31, 2020
AGA Guidelines on the gastrointestinal evaluation of iron deficiency anemia
1 Sep, 2020 | 06:02h | UTC
Choosing Wisely: Five low-value or harmful practices that should be avoided in pediatric pulmonology and sleep medicine
1 Sep, 2020 | 05:57h | UTCCommentary: Choosing Wisely: 5 Practices to Avoid in Pediatric Pulmonology and Sleep Medicine – NEJM Journal Watch
See complete lists of low-value practices: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia AND Choosing Wisely Canada
Perspective: COVID-19 vaccine trials should seek worthwhile efficacy
31 Aug, 2020 | 01:45h | UTCCOVID-19 vaccine trials should seek worthwhile efficacy – The Lancet
Commentary: Covid vaccine rush could make pandemic worse, say scientists – The Guardian
Commentary on Twitter
"Although efficacy far greater than 50% would be better, efficacy of about 50% would represent substantial progress"
Philip Krause et al for the @WHO Solidarity Vaccines Trial Expert Group on why #COVID19 vaccine trials should seek worthwhile efficacy https://t.co/2VWas8YU7L pic.twitter.com/RjbeZkeAE0
— The Lancet (@TheLancet) August 28, 2020
Study: Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2
31 Aug, 2020 | 01:47h | UTCRelated study: Salivary Detection of COVID-19 – Annals of Internal Medicine
Commentary on Twitter
Just published @NEJM
Strong support for saliva as an alternative to nasopharyngeal swab samples to detect #SARSCoV2
by @awyllie13 @YaleSPH and team @YaleMed https://t.co/waF5ODmiV8 pic.twitter.com/zw1D2JqW0y— Eric Topol (@EricTopol) August 28, 2020
Children might play a bigger role in COVID transmission than first thought. Schools must prepare
31 Aug, 2020 | 01:41h | UTC
A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU
31 Aug, 2020 | 01:44h | UTC
#ESCCongress – [Abstract Only] Randomized trial: Cardiovascular and renal outcomes with Empagliflozin in heart failure
31 Aug, 2020 | 01:38h | UTCCommentaries: EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF – TCTMD AND EMPEROR-Reduced meets primary endpoint in heart failure with reduced ejection fraction – European Society of Cardiology AND Empagliflozin Outcome Trial in Patients With Chronic Heart Failure and a Reduced Ejection Fraction – EMPEROR-Reduced – American College of Cardiology
Related study: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction – New England Journal of Medicine
Commentary on Twitter
Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
— NEJM (@NEJM) August 29, 2020
#ESCCongress – [Abstract Only] Randomized trial: Early rhythm-control therapy in patients with atrial fibrillation
31 Aug, 2020 | 01:39h | UTCEarly Rhythm-Control Therapy in Patients with Atrial Fibrillation – New England Journal of Medicine
Commentaries: Early rhythm control therapy improves outcomes in patients with atrial fibrillation – European Society of Cardiology AND Rhythm Control Cuts First CV Events in Early Atrial Fibrillation: EAST-AFNET 4 – TCTMD AND Early Treatment of Atrial Fibrillation for Stroke Prevention Trial – EAST-AFNET 4 – American College of Cardiology AND EAST-AFNET 4: Is Early Rhythm-Control Therapy Associated With Lower Risk of CV Outcomes in Early AFIB Patients? – American College of Cardiology
Commentary on Twitter
Original Article: Early Rhythm-Control Therapy in Patients with Atrial Fibrillation (EAST–AFNET 4 Trial) #ESCCongress
— NEJM (@NEJM) August 29, 2020
#ESCCongress – [Abstract Only] Randomized trial: aspirin with or without clopidogrel after transcatheter aortic-valve implantation
31 Aug, 2020 | 01:33h | UTCCommentaries: Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic-Valve Implantation – POPular TAVI (antiplatelet therapy) – American College of Cardiology AND Go With Aspirin Alone After TAVR When Anticoagulation Isn’t Needed: POPular TAVI – TCTMD
Commentary on Twitter
#ESCCongress #popular_TAVI
Aspirin vs Asp+Clop following #TAVR Aspirin alone:
➡️decrease in bleeding by 40%
➡️No increase in ischemic events
➡️ RRR 26% for net benefit@aayshacader @AnastasiaSMihai @mirvatalasnag @sbrugaletta @Ortega_Paz @willsuh76 @SVRaoMD @DrAsifQasim @iamritu pic.twitter.com/CvUdYgw5mG— Mamas A. Mamas (@mmamas1973) August 30, 2020
#ESCCongress – [Abstract Only] SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
31 Aug, 2020 | 01:36h | UTC
#ESCCongress – Initial invasive versus conservative management of stable ischemic heart disease patients with a history of heart failure or left ventricular dysfunction: Insights from the ISCHEMIA Trial
31 Aug, 2020 | 01:30h | UTC
Commentary on Twitter
ISCHEMIA Trial: In patients w/ischemia & CHF (LVEF 35-45%), an early invasive strategy might improve event-free survival #CircESC20 #ESCCongress #AHAJournals @RenatoDLopes1 @DCRINews @DukeHeartCenter @AHAScience https://t.co/G5FDD7ipL9 pic.twitter.com/joYIxGx544
— Circulation (@CircAHA) August 29, 2020
#ESCCongress – [Abstract Only] Randomized trial: Low-dose edoxaban in very elderly patients with atrial fibrillation
31 Aug, 2020 | 01:32h | UTCCommentaries: Edoxaban Low-Dose for Elder Care Atrial Fibrillation – ELDERCARE-AF – American College of Cardiology AND ELDERCARE-AF: Edoxaban Superior to Placebo in Preventing Stroke, Systemic Embolism in Elderly Japanese AFib Patients – American College of Cardiology
Commentary on Twitter
Elderly patients with AF who were not candidates for standard doses of oral anticoagulants because of a high risk of bleeding were assigned to receive 15 mg of edoxaban or placebo once daily. Edoxaban was superior to placebo in preventing stroke or systemic embolism. #ESCCongress
— NEJM (@NEJM) August 30, 2020
#ESCCongress – Randomized trial: Colchicine not beneficial for patients with acute coronary syndrome
31 Aug, 2020 | 01:26h | UTCCommentaries: Colchicine to Improve Cardiovascular Outcomes in ACS Patients – COPS – Circulation
Commentary on Twitter
Colchicine in Patients with Acute Coronary Syndrome: The Australian COPS RCT vs COLCOT RCT #ESCCongress 🔴 seemingly opposite results, dose start time patients? @almucastro01 @ValleAlfonso @JoseJuanatey @Dr_Manito @secardiologia @varrarte @sociedadSEEN 🤔🩺https://t.co/uagW2HRGPt pic.twitter.com/SQoVsbzG0m
— Oscar Moreno # (@moreno_perez_o) August 30, 2020
#ESCCongress – Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
31 Aug, 2020 | 01:23h | UTCCommentary: Colchicine Cardiovascular Outcomes Trial – COLCOT – American College of Cardiology
Commentary on Twitter
#ESCCongress #COLCOT Study looking at TTI colchicine to assess if timing impacted outcomes
❤️ACS treatment with colchicine 🆚 placebo: 23%⤵️ in events
❤️Randomized w/in 30days postMI
🔺TTI (Time to Treat Initiation) 0-3d 🆚 4-7d 🆚 8-30d
🔺0-3 days had better outcomes pic.twitter.com/iQAkts1BG9— Dr. Martha Gulati ♥️🫀❤️🩹🇨🇦 (@DrMarthaGulati) August 30, 2020
#ESCCongress – [Abstract Only] Randomized trial: Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy
31 Aug, 2020 | 01:21h | UTCCommentary: EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class – TCTMD
Commentary on Twitter
Latebreaking now at #ESCCongress—Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial https://t.co/JcJnGI0VVt pic.twitter.com/Xmf98Bcoir
— The Lancet (@TheLancet) August 29, 2020
#ESCCongress – 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
31 Aug, 2020 | 01:20h | UTCNews Release: How to treat the most common heart attacks – European Society of Cardiology
Commentary: 2020 ESC NSTE-ACS Guidelines: Key Points – American College of Cardiology
Commentary on Twitter
ESC 2020 Guidelines for non-ST elevation acute coronary syndrome just released https://t.co/dKIngRO59K#ESCCongress #ESCGuidelines #cardiotwitter #MedTwitter pic.twitter.com/ihcnxcCzBw
— European Society of Cardiology (@escardio) August 29, 2020